CYCN Cyclerion Therapeutics

Cyclerion to Present at the J.P. Morgan Healthcare Conference

Cyclerion to Present at the J.P. Morgan Healthcare Conference

– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases –

CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will present at the J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 9AM PST (6AM EST) at the Westin St. Francis in San Francisco in the Elizabethan A Room.  The company will also present ongoing and future clinical development plans.

A live webcast of the presentation can be accessed at: . An archived replay of the webcast will be available for approximately 90 days following the presentation. 

About Cyclerion Therapeutics   

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs include praliciguat which recently completed Phase 2 studies and which the company intends to out-license for further development in diabetic nephropathy, olinciguat in Phase 2 development for sickle cell disease, IW-6463 in Phase 1 development for serious and orphan CNS diseases, and two preclinical programs targeting serious liver and lung diseases, respectively. 

For more information about Cyclerion, please visit  and follow us on Twitter () and LinkedIn ().  

Contact 

Carlo Tanzi, Ph.D. 

Kendall Investor Relations 

617-914-0008 

 

EN
23/12/2019

Underlying

CYCNCyclerion Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cyclerion Therapeutics

 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof...

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board –Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept (“POC”) Study in Treatment Resistant Depression (“TRD”) in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIR...

February 17, 2026 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and...

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression – Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept (“POC”) Study in the Second Half of 2026 – – Webcast Being Held on January 6, 2026 at 8:00 a.m. ET, Featuring Key Opinion Leader, Dr. Husseini Manji – CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cycle...

January 5, 2026 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Co...

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company – Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology (“MIT”), securing the intellectual property that will serve as the cornerstone of its strategic relaunch. This agreement...

September 23, 2025 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Comp...

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strat...

December 17, 2024 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Regina Graul, Ph.D., Promoted to Chief Executive Officer CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December 2023, she has strengthened all aspects of the company. She has been working closely with the Board of Directors to prioritize building shareholder value by reducing Cyclerion’s operating costs while leading a world-class search and evaluati...

August 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch